Full Press Release Details
at Three Upcoming Investor Conferences in September
Henderson, Nev. - September 3,
2024 - Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing
novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will
present at three upcoming investor conferences in September.
H.C. Wainwright 26th Annual Global Investment Conference
Details: Presenting on Wednesday, September 11, 2024, at 11:30 a.m. ET
and hosting investor meetings in New York, NY.
Event: Stifel Immunology and
Inflammation Virtual Summit
Details: Presenting on Tuesday, September 17, 2024, at 12:00 p.m. ET and hosting virtual investor meetings.
Event: Cantor Global Healthcare Conference
Details: Presenting on Tuesday, September 17, 2024, at 2:30 p.m. ET and hosting investor meetings in New York, NY.
Links for live webcasts and replays, if
available, will be posted on the News & Events page in the Investors & Media section of the Zura Bio website.
Presentations will be archived on the website for at least 30 days following the event.
Zura Bio is a clinical-stage, multi-asset immunology company developing
novel dual-pathway antibodies for autoimmune and inflammatory diseases. Currently, Zura Bio is developing three assets which have completed
Phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug
(ZB-168), and torudokimab (ZB-880), with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory
diseases, including systemic sclerosis and other novel indications with unmet needs.
Head of Investor Relations